|Bid||1.1500 x 800|
|Ask||1.1800 x 4000|
|Day's Range||1.1500 - 1.1863|
|52 Week Range||0.8200 - 1.9500|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Infinity (INFI) delivered earnings and revenue surprises of -11.11% and -59.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals, Inc. will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the company.
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
-- MARIO-3 Phase 2 Study to Evaluate Triple Combination Therapy with IPI-549 in the Frontline Setting in Triple Negative Breast Cancer and Renal Cell Cancer -- -- Phase 1/ 1b Study with Arcus Biosciences ...
CAMBRIDGE, Mass. , Sept. 3, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology ...
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., Aug. 22, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) today announced that Samuel Agresta, M.D., will transition from his role as Chief Medical Officer to Infinity's Board of Directors and Research and Development Committee. "I joined Infinity due to the incredible potential of IPI-549 and remain convinced of this potential due to our Phase 1 clinical and translational data, both as a monotherapy and in combination with Opdivo®," said Dr. Agresta. "These data have enabled the advancement of IPI-549 into a comprehensive Phase 2 program with world class partners which includes a randomized global study in bladder cancer.
Infinity (INFI) delivered earnings and revenue surprises of -20.00% and -90.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Initiated MARIO-275 Global, Randomized Phase 2 Study in I/O Naïve Urothelial Cancer -- -- Initiating MARIO-3 Phase 2 Study in Front-Line Triple Negative Breast and Renal Cell Cancer in 3Q -- CAMBRIDGE, ...
CAMBRIDGE, Mass. , July 23, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, July 30, 2019 at 8:00 a.m. ET to review its second quarter 2019 financial ...
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
CAMBRIDGE, Mass. , May 29, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that members of the management team will be participating in the 2019 BIO International Convention ...
CAMBRIDGE, Mass. , May 16, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the ...
Infinity (INFI) delivered earnings and revenue surprises of -380.00% and -78.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 24 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...